Literature DB >> 11042701

Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells.

A J Canhoto1, A Chestukhin, L Litovchick, J A DeCaprio.   

Abstract

The retinoblastoma family of proteins including pRB, p107 and p130 undergoes cell cycle dependent phosphorylation during the mid-G1 to S phase transition. This phosphorylation is dependent upon the activity of cyclin D/cdk4. In contrast to pRB and p107, p130 is phosphorylated during G0 and the early G1 phase of the cell cycle. We observed that p130 is specifically phosphorylated on serine and threonine residues in T98G cells arrested in G0 by serum deprivation or density arrest. Identification of the phospho-serine and phospho-threonine residues revealed that most were clustered within a short co-linear region unique to p130, defined as the Loop. Deletion of the Loop region resulted in a change in the phosphorylation status of p130 under growth arrest conditions. Notably, deletion of the Loop did not affect the ability of p130 to bind to E2F-4 or SV40 Large T antigen, to induce growth arrest in Saos-2 cells, and to become hyperphosphorylated during the proliferative phase of the cell cycle. p130 undergoes specific G0 phosphorylation in a manner that distinguishes it from pRB and p107.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042701     DOI: 10.1038/sj.onc.1203893

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Pocket protein p130/Rb2 is required for efficient herpes simplex virus type 1 gene expression and viral replication.

Authors:  G L Ehmann; H A Burnett; S L Bachenheimer
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism.

Authors:  Anton Chestukhin; Larisa Litovchick; Katherine Rudich; James A DeCaprio
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

3.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

Authors:  Y Ma; W D Cress
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

4.  Integrated stability and activity control of the Drosophila Rbf1 retinoblastoma protein.

Authors:  Liang Zhang; Yiliang Wei; Irina Pushel; Karolin Heinze; Jared Elenbaas; R William Henry; David N Arnosti
Journal:  J Biol Chem       Date:  2014-07-21       Impact factor: 5.157

5.  Loss of p27(Kip1) enhances the transplantation efficiency of hepatocytes transferred into diseased livers.

Authors:  A N Karnezis; M Dorokhov; M Grompe; L Zhu
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

6.  Regulation of aurora B expression by the bromodomain protein Brd4.

Authors:  Jianxin You; Qing Li; Chong Wu; Jina Kim; Matthias Ottinger; Peter M Howley
Journal:  Mol Cell Biol       Date:  2009-07-13       Impact factor: 4.272

7.  Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2.

Authors:  Taylor P Enrico; Wayne Stallaert; Elizaveta T Wick; Peter Ngoi; Xianxi Wang; Seth M Rubin; Nicholas G Brown; Jeremy E Purvis; Michael J Emanuele
Journal:  Elife       Date:  2021-12-01       Impact factor: 8.140

8.  Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130.

Authors:  Jan-Hermen Dannenberg; Leontine Schuijff; Marleen Dekker; Martin van der Valk; Hein te Riele
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

9.  Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence.

Authors:  Larisa Litovchick; Anton Chestukhin; James A DeCaprio
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 10.  Role of the Holoenzyme PP1-SPN in the Dephosphorylation of the RB Family of Tumor Suppressors During Cell Cycle.

Authors:  Eva M Verdugo-Sivianes; Amancio Carnero
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.